NIAID-funded study could offset harsh effects of antibiotics.
Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation. In their study, patients who underwent the procedure were randomly assigned into two groups: one group received standard care and the other received auto-FMT. The researchers found that auto-FMT resulted in the recovery of beneficial gut bacteria to near baseline levels within days, thus restoring patients’ digestive, immune and other essential functions. With standard care, beneficial bacteria typically take many weeks to recover from antibiotic treatment, leaving patients at risk of other infectious diseases, including Clostridium difficile.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, provided funding for part of the project. The study report appears in Science Translational Medicine.
“This important study suggests that clinical intervention using auto-FMT can safely reverse the disruptive effects of broad-spectrum antibiotic treatment,” says NIAID Director Anthony S. Fauci, M.D. “If validated in larger studies, this approach may prove to be a relatively simple way to quickly restore a person’s healthy microbiome following intensive antimicrobial therapy.”
Allogenic hematopoietic cell transplantation involves a donor — often but not exclusively a family member — who gives the recipient stem cells that re-establish bone marrow production of blood cells and immune function to combat cancer. Antibiotics are essential to prevent bacterial infections in stem cell recipients. However, antibiotics also destroy beneficial bacteria that enhance immune function and resistance to infection. The loss of beneficial bacteria increases the risk of certain life-threatening infectious diseases and graft-versus-host disease (GVHD).
The study involved cancer patients who provided their own fecal sample, which was frozen and stored prior to their cell transplantation procedure. Weeks later, when physicians confirmed that the transplanted cells were growing, they assessed the status of the patients’ beneficial gut bacteria. The first 25 patients who lacked known beneficial bacteria were enrolled into the study and randomly assigned to the different treatment groups: 14 received auto-FMT by enema and 11 received standard-of-care.
The patients who received auto-FMT consistently regained bacterial diversity, composition and function; recovery of beneficial bacteria in the 11 control patients was delayed.
The researchers are continuing to monitor the study patients to determine if auto-FMT improves patient outcomes, such as the incidence and severity of bacterial, viral and fungal infections and the incidence and severity of GVHD. Whether FMT from a healthy donor would be as beneficial as the patient’s own fecal sample at restoring beneficial bacteria remains to be studied.
Learn more: Fecal microbiota transplantation helps restore beneficial bacteria in cancer patients
The Latest on: Fecal microbiota transplantation
[google_news title=”” keyword=”fecal microbiota transplantation” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Fecal microbiota transplantation
- Fecal Transplant Shows Promise for Easing Inflammatory Bowel Disease Symptomson April 25, 2024 at 4:45 pm
For the study, scientists reviewed results from 15 clinical trials that tested fecal microbiota transplants (FMT) — when stool with healthy microorganisms is inserted into a sick patient’s digestive ...
- Belgian Man With Auto-Brewery Syndrome Acquitted Of Drunk Driving: How To Diagnose, Treat This Conditionon April 25, 2024 at 2:46 am
Auto Brewery Syndrome is a complex and often misunderstood condition that requires careful diagnosis and management ...
- Seed Health Appoints Microbiome Pioneer Zain Kassam, M.D., M.P.H., as Chief Medical Officeron April 24, 2024 at 5:15 am
Seed Health, a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal ...
- Microbiome Alterations Link to Growth Hormone Deficiencyon April 19, 2024 at 4:56 am
Growth hormone deficiency appears to be linked to a particular microbiome signature that could help with the early diagnosis and treatment of short stature, suggest study.
- Researchers conclude fecal transplants can rid patients of resistant gut bacteriaon April 16, 2024 at 12:28 pm
Transferring fecal microbiota from healthy donors to the intestines of chronically ill people has beneficial effects on these recipients' gut bacteria, also in the longer term. This is the conclusion ...
- Causal Relationship Between Gut Microbial Genera and Risk for Hyperuricemia Confirmedon April 15, 2024 at 5:00 pm
The presence of Escherichia-Shigella increased the risk for hyperuricemia, while Family XIII AD3011 and Lachnospiraceae NC2004 groups were associated with a reduced risk. Gout, a prevalent condition ...
- How Is SIBO Treated?on April 13, 2024 at 5:30 am
SIBO is typically treated with antibiotics and dietary supplements to replenish nutrient deficiencies. Dietary changes and fecal transplants may also help.
- Breakthrough: Poo transplant can slow Parkinson’s symptomson April 13, 2024 at 4:00 am
Parkinson's motor symptoms were improved in a clinical study in which early-stage patients were given fecal transplants.
- How Is Clostridiodes Difficile (C. Diff) Treated?on April 12, 2024 at 9:00 am
Medically reviewed by Jay N. Yepuri, MD Infection with the Clostridioles difficile (C. diff, or C. difficile) bacteria is a leading cause of diarrhea and colitis (colon, or large intestine, ...
via Bing News